AstraZeneca Pharma India and Mankind Pharma entered into an agreement for exclusive distribution of AstraZeneca`s budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India. AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder (MAH) and import license.Powered by Capital Market - Live News

Net profit of Astrazeneca Pharma India declined 46.08% to Rs 15.80 crore in the quarter ended December 2023 as against Rs 29.30 crore during the previous quarter ended December 2022. Sales rose 22.41% to Rs 305.79 crore in the quarter ended December 2023 as against Rs 249.81 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales305.79249.81 22 OPM %4.9214.65 - PBDT24.0943.59 -45 PBT20.3939.46 -48 NP15.8029.30 -46 Powered by Capital Market - Live News

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 8 February 2024.Powered by Capital Market - Live News

Net profit of Astrazeneca Pharma India rose 60.84% to Rs 52.37 crore in the quarter ended September 2023 as against Rs 32.56 crore during the previous quarter ended September 2022. Sales rose 31.74% to Rs 311.07 crore in the quarter ended September 2023 as against Rs 236.13 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales311.07236.13 32 OPM %16.9617.25 - PBDT60.6247.36 28 PBT56.9544.07 29 NP52.3732.56 61 Powered by Capital Market - Live News

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 9 November 2023.Powered by Capital Market - Live News